AstraZeneca to Harness Benefits of Genome-Editing Technology
By Marta Falconi (The Wall Street Journal) – ZURICH—British drug maker AstraZeneca PLC unveiled agreements on Thursday that should enable the pharmaceutical company to tap into a promising, nascent gene technology aimed at making drugs more precise.